|
Photocure ASA is a Norwegian pharmaceutical company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology, targeting key dermatology and oncology markets. Photocure's strategy is to build a speciality pharma company by developing and commercialising new and innovative products based on its patented photodynamic technology. Photocure’s strategy in dermatology is to continue the development of the dermatology portfolio, with Visonac and other new dermatology products, and build a commercial platform in the US. Photocure's strategy in cancer is to continue the commercialisation of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. ==History== Photocure was founded in 1993 and Photocure's aim was to commercialise photodynamic technologies developed by the Norwegian Radium Hospital, the largest comprehensive cancer centre in Northern Europe. In 1997 Photocure recruited the first full-time employee and started off formal clinical studies for Metvix. In 2000 the company filed their first marketing authorisation for Metvix and the company's share were listed on the Oslo Stock Exchange. In 2000 Photocure started clinical studies on Hexvix. Photocure's obtained their first marketing authorisation for Metvix the year after, and Metvix and Aktilite were marketed for the first time. A licensing agreement for Metvix was signed with Galderma and all rights to Metvix/Aktilite were sold to Galderma in 2009. In 2005 Hexvix got approved in all EU/EEA countries and Hexvix was launched in Europe in 2006. Photocure signed a licensing agreement with GE Healthcare for Hexvix. Hexvix was FDA approved in the US in May 2010 under the tradename Cysview. Lumacan was licensed to Salix Pharmaceuticals Inc. in 2010.〔(Photocure signs agreement with Salix Pharmaceuticals for Lumacan(TM) ) NewsWeb 22 Okt 2010〕 In 27. September 2011 Photocure launched a new commercial strategy for Hexvix/Cysview. Photocure will commercialize Cysview directly in the US market, and continue commercialization of Hexvix in Nordic. Photocure entered into a strategic collaboration with Ipsen, and Ipsen territory will we global without USA and Nordics. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Photocure」の詳細全文を読む スポンサード リンク
|